Studies have shown that activated AMPK can inhibit ACC activity by downregulating the expression of SREBP-1c, thereby inhibiting cholesterol and fatty acid synthesis, reducing hepatic lipid synthesis, and improving hepatic steatosis [29,30,31]. Here, SREBF1 is linked to fatty liver disease.